Skip to content

Study · Animal study (in vivo) · mouse · 2020

7 results

Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.

Norona J, Apostolova P, Schmidt D, Ihlemann R, Reischmann N, Taylor G, Köhler N, de Heer J, Heeg S, Andrieux G, Siranosian BA, Schmitt-Graeff A and 15 more

Show all authors

Pfeifer D, Catalano A, Frew IJ, Proietti M, Grimbacher B, Bulashevska A, Bhatt AS, Brummer T, Clauditz T, Zabelina T, Kroeger N, Blazar BR, Boerries M, Ayuk F, Zeiser R

Blood1 Sept 2020Cited by 99 (Europe PMC)

PMID32542357 (opens in a new tab)PMCIDPMC7498363 (opens in a new tab)DOI10.1182/blood.2020005957 (opens in a new tab)PepBankPUB-32542357
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mouse models, teduglutide reduced de novo acute GVHD.

    In plain wordsIn mice, teduglutide reduced new acute GVHD.

    Peptide
    Teduglutide
    Outcome
    DecreaseDe novo acute GVHD
    Study

    mousen: not reported in source

    GVHD mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refractory GVHD, without compromising graft-versus-leukemia (GVL) effects in multiple mouse models.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mouse models, teduglutide reduced steroid-refractory GVHD.

    In plain wordsIn mice, teduglutide reduced GVHD that resisted steroids.

    Peptide
    Teduglutide
    Outcome
    DecreaseSteroid-refractory GVHD
    Study

    mousen: not reported in source

    GVHD mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refractory GVHD, without compromising graft-versus-leukemia (GVL) effects in multiple mouse models.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mouse models, teduglutide did not compromise graft-versus-leukemia effects.

    In plain wordsIn mice, teduglutide did not compromise graft-versus-leukemia effects.

    Peptide
    Teduglutide
    Outcome
    No significant changeGraft-versus-leukemia effects
    Study

    mousen: not reported in source

    GVHD mouse models
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refractory GVHD, without compromising graft-versus-leukemia (GVL) effects in multiple mouse models.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In GVHD mouse models, GLP-2 substitution with teduglutide promoted Paneth cell regeneration.

    In plain wordsIn mice with GVHD, teduglutide promoted Paneth cell regeneration.

    Peptide
    Teduglutide
    Outcome
    IncreasePaneth cell regeneration
    Study

    mousen: not reported in source

    GVHD mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically GLP-2 substitution promoted regeneration of PCs and ISCs, which enhanced production of antimicrobial peptides and caused microbiome changes.
    1 context sentence
    Summary · context
    Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refractory GVHD, without compromising graft-versus-leukemia (GVL) effects in multiple mouse models.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In GVHD mouse models, GLP-2 substitution with teduglutide promoted intestinal stem cell regeneration.

    In plain wordsIn mice with GVHD, teduglutide promoted intestinal stem cell regeneration.

    Peptide
    Teduglutide
    Outcome
    IncreaseIntestinal stem cell regeneration
    Study

    mousen: not reported in source

    GVHD mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically GLP-2 substitution promoted regeneration of PCs and ISCs, which enhanced production of antimicrobial peptides and caused microbiome changes.
    1 context sentence
    Summary · context
    Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refractory GVHD, without compromising graft-versus-leukemia (GVL) effects in multiple mouse models.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In GVHD mouse models, teduglutide-associated cell regeneration enhanced antimicrobial peptide production.

    In plain wordsIn mice with GVHD, cell regeneration after teduglutide enhanced antimicrobial peptide production.

    Peptide
    Teduglutide
    Outcome
    IncreaseAntimicrobial peptide production
    Study

    mousen: not reported in source

    GVHD mouse models
    Outcome group
    Immune response · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically GLP-2 substitution promoted regeneration of PCs and ISCs, which enhanced production of antimicrobial peptides and caused microbiome changes.
    1 context sentence
    Summary · context
    Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refractory GVHD, without compromising graft-versus-leukemia (GVL) effects in multiple mouse models.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In GVHD mouse models, teduglutide-associated cell regeneration caused microbiome changes.

    In plain wordsIn mice with GVHD, cell regeneration after teduglutide changed the microbiome.

    Peptide
    Teduglutide
    Outcome
    Direction not reportedMicrobiome changes
    Study

    mousen: not reported in source

    GVHD mouse models
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically GLP-2 substitution promoted regeneration of PCs and ISCs, which enhanced production of antimicrobial peptides and caused microbiome changes.
    1 context sentence
    Summary · context
    Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refractory GVHD, without compromising graft-versus-leukemia (GVL) effects in multiple mouse models.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.